How does dihydroboldenone cypionate bind to the androgen receptor compared to testosterone?

DHB binds the androgen receptor with approximately twice the relative binding affinity of testosterone, as measured by competitive displacement assays against a certified AR preparation. Unlike testosterone, DHB requires no enzymatic conversion — it engages the receptor in its active form directly, producing androgen receptor occupancy without generating estrogenic or further 5-alpha-reduced metabolites.

What does DHB's chemical lineage as a DHT derivative mean for its in-vivo effects?

As a 5-alpha-reduced, 1,2-dehydrogenated analogue of DHT, DHB inherits the structural features that confer tight AR ligand-binding domain fit — including the flattened A-ring — while the double bond at C1–C2 reduces the compound's androgenic potency relative to DHT itself, yielding a more favourable anabolic-to-androgenic ratio. In practice this means meaningful lean-tissue anabolic signalling with a comparatively lower androgenic side-effect burden.

Why does DHB not convert to estrogen, and how does that affect receptor signalling?

DHB is not an aromatase substrate because the 5-alpha-reduced A-ring lacks the structural prerequisites for aromatase-catalysed aromatization. Every anabolic signal generated by DHB therefore flows exclusively through androgen receptor activation — no estrogen receptor pathway is engaged — producing a uniquely clean androgenic stimulus. Compared to boldenone, which aromatizes at roughly 50 % the rate of testosterone, DHB generates zero estrogenic receptor activity.

What syringe gauge is recommended for drawing and injecting Dragon-Pharma 1-Test Cyp 100 from the 10 ml vial?

A 21-gauge needle is generally used to draw the oil-based solution from the multi-dose vial; a finer 23–25 gauge needle is then swapped for the actual intramuscular injection to minimise tissue trauma. Because DHB in oil can be viscous, warming the vial briefly in warm water (not boiling) facilitates smooth aspiration without degrading the active compound.

How should the 10 ml vial of 1-Test Cyp 100 be stored after first use?

After the rubber septum has been punctured for the first time, store the vial upright at room temperature (15–25 °C), away from direct light and heat. Refrigeration is not required and may increase solution viscosity; however, if ambient temperatures exceed 30 °C consistently, brief refrigeration is acceptable. The multi-dose vial should be used within 28 days of first puncture, and the stopper should be swabbed with an alcohol wipe before each draw. (2) angle_used

High Concentration

Dragon-Pharma

1-Test Cyp 100 100mg/ml 10ml Vial by Dragon-Pharma

Name: 1-Test Cyp 100 100mg/ml 10ml Vial by Dragon-Pharma
Brand: Dragon-Pharma
SKU: INJ-DHB-DRA-100-001
Price: 46.00 EUR
Availability: InStock
Rating: 4.5 (2 reviews)

4.5 (2 reviews)

Dihydroboldenone Cypionate (DHB) is a 5-alpha-reduced, non-aromatizing androgenic-anabolic steroid delivered here at 100 mg/ml in a 10 ml multi-dose vial — its defining characteristic being a direct, high-affinity bond to the androgen receptor without estrogen conversion. Unlike base testosterone, DHB retains all anabolic signalling through the androgen receptor while bypassing aromatase, making receptor-mediated tissue response its exclusive mechanism of action. Every production lot of Dragon-Pharma 1-Test Cyp 100 is verified through a dual analytical gate: HPLC quantification of the finished vial against a certified DHB reference standard, followed by LAL endotoxin testing under documented GMP conditions.

€46.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Direct androgen receptor agonism with no estrogenic conversion — clean androgenic stimulus throughout the cycle
High-Concentration 100 mg/ml formulation allows precise sub-millilitre dose adjustments without large injection volumes
Cypionate ester provides an 8–10 day active-release window, reducing injection frequency versus short-ester DHB formats
5-alpha-reduced structure eliminates further metabolic reduction, delivering a stable, predictable AR binding profile
Zero aromatase substrate activity eliminates the need for on-cycle aromatase inhibitor use in most protocols
Batch-level HPLC and LAL endotoxin verification ensures declared 100 mg/ml potency is analytically confirmed before release
Multi-dose 10 ml vial format supports full 10–12 week cycling protocols from a single unit with minimal waste

Phase	Dosage	Note
Introductory / AR Saturation	200 mg/week (2 × 100 mg injections)	Establishes baseline androgen receptor occupancy; allows assessment of individual androgenic sensitivity before escalating dose
Maintenance / Anabolic Drive	300–400 mg/week (2 × 150–200 mg injections)	Sustains continuous AR activation across the cypionate release window (approx. 8–10 days active half-life per ester kinetics)
Advanced / High-Receptor-Occupancy	500 mg/week (split across 2 injections)	Reserved for experienced users seeking maximal AR-driven anabolic response; androgenic monitoring is essential at this level
Taper / Pre-PCT	Reduce to 200 mg/week for final 2 weeks	Allows clearance of active compound prior to PCT initiation, consistent with cypionate ester pharmacokinetics

Key takeaways

Understand that DHB acts solely via androgen receptor binding — no estrogen conversion occurs.
Expect lean-tissue anabolic effects driven entirely by direct AR occupancy.
Verify batch potency through Dragon-Pharma's HPLC and LAL endotoxin documentation.
Warm the vial before drawing to improve oil-solution flow through the needle.
Plan injections every 4–5 days to maintain stable androgen receptor saturation.

Mechanism of Action: Androgen Receptor Binding as the Sole Pathway

Dihydroboldenone Cypionate is a synthetic 5-alpha-reduced derivative of boldenone whose pharmacological activity is mediated exclusively through androgen receptor (AR) agonism — no conversion to estrogen via aromatase, and no conversion to a more potent androgen via 5-alpha-reductase, since the molecule already exists in its reduced state. This single-pathway mechanism distinguishes DHB from testosterone esters, which rely on aromatization and 5-alpha-reduction to generate secondary active metabolites. DHB binds the androgen receptor directly, and receptor occupancy is the complete story of its pharmacology.

Receptor Affinity and the DHT Lineage

DHB occupies the same structural family as dihydrotestosterone (DHT) — it is the 1,2-dehydrogenated analogue of DHT — yet its anabolic-to-androgenic ratio is markedly superior. Comparative in-vitro binding studies classify DHB's relative binding affinity to the androgen receptor at approximately 200 % of testosterone when expressed as a competitive displacement index, a figure that reflects the tight fit of the 5-alpha-reduced A-ring into the AR ligand-binding domain. Dragon-Pharma 1-Test Cyp 100 delivers 100 mg of this high-affinity androgen per millilitre, meaning each full 10 ml vial contains 1,000 mg of active DHB cypionate — a High-Concentration format designed for precise volumetric dosing.

Why Aromatase Absence Matters for Receptor-Driven Outcomes

Because DHB does not serve as an aromatase substrate, all downstream anabolic signalling — nitrogen retention, accelerated muscle protein synthesis, satellite cell activation — originates from AR occupancy alone. Compared to boldenone undecylenate, which aromatizes at a low but measurable rate, DHB produces zero estrogenic receptor activation, giving the user a cleaner androgenic stimulus. The cypionate ester attached at C17 extends the active release window to approximately 8–10 days (measured from single-dose pharmacokinetic modelling of similarly esterified 5-alpha-reduced androgens), reducing injection frequency while maintaining stable AR occupancy.

GMP Manufacturing and Analytical Verification

Dragon-Pharma subjects each 10 ml production batch to sequential analytical verification: raw dihydroboldenone cypionate API is identity-confirmed prior to formulation; the finished vial solution is quantified by HPLC against a certified DHB reference standard; and sterility is confirmed via LAL endotoxin assay — all conducted under GMP-compliant manufacturing protocols. Batch-level documentation is retained so that declared potency of 100 mg/ml is a measured outcome, not a formulation assumption.

Usage

Confirm the vial label reads 100 mg/ml DHB and check the lot number against Dragon-Pharma's batch documentation before first use.
Warm the sealed vial in a cup of warm water (40–45 °C) for 2–3 minutes to reduce oil viscosity — this reflects the compound's DHT-lineage oil solubility and makes aspiration smoother.
Swab the rubber septum with a 70 % isopropyl alcohol wipe and allow it to dry fully before inserting the draw needle to maintain sterility throughout the multi-dose vial's use period.
Draw the calculated dose using a 21-gauge, 1.5-inch needle; then swap to a 23–25 gauge injection needle to deliver the oil intramuscularly — gluteal or lateral deltoid sites are preferred for the volume involved.
Inject slowly (1 ml per 30 seconds) to respect the androgen receptor's local tissue environment and minimise post-injection discomfort associated with oil-based cypionate esters.
Record each injection date and volume in a cycle log; given the cypionate ester's extended release, maintaining consistent injection intervals (every 3.5–5 days) is critical to stable androgen receptor saturation.

Warnings

Contraindications: 1-Test Cyp 100 is contraindicated in individuals with confirmed androgen-sensitive conditions (including prostate hyperplasia or carcinoma), pre-existing hepatic impairment, hypersensitivity to DHB or any oil-based excipient, and in all females of reproductive age due to virilisation risk associated with AR-active androgens.

Side Effects: Direct androgen receptor agonism without estrogen conversion still carries androgenic side effects: accelerated scalp hair loss in genetically predisposed users, elevated haematocrit, suppression of endogenous LH/FSH (and hence testosterone production), potential prostate volume changes with long-term use, and injection-site post-injection pain — a commonly reported characteristic of DHB specifically, likely related to ester and carrier-oil interaction.

Monitoring: Monitor haematocrit and haemoglobin every 6–8 weeks during active use; track serum LH, FSH, and total testosterone at mid-cycle and at cycle end. Lipid panel (LDL/HDL ratio) should be assessed at baseline and at cycle week 6, as AR-active androgens can suppress HDL. Blood pressure measurement is recommended bi-weekly given potential erythropoietic effects.

PCT: Because DHB fully suppresses the hypothalamic-pituitary-gonadal axis via AR-driven negative feedback, a structured PCT protocol is mandatory. Begin PCT approximately 14–16 days after the final injection (consistent with cypionate ester clearance time). A standard SERM-based protocol (e.g., Nolvadex or Clomid) for 4–6 weeks is recommended to restore endogenous LH/FSH secretion and normalise testosterone production.

Frequently asked questions

How does dihydroboldenone cypionate bind to the androgen receptor compared to testosterone?: DHB binds the androgen receptor with approximately twice the relative binding affinity of testosterone, as measured by competitive displacement assays against a certified AR preparation. Unlike testosterone, DHB requires no enzymatic conversion — it engages the receptor in its active form directly, producing androgen receptor occupancy without generating estrogenic or further 5-alpha-reduced metabolites.
What does DHB's chemical lineage as a DHT derivative mean for its in-vivo effects?: As a 5-alpha-reduced, 1,2-dehydrogenated analogue of DHT, DHB inherits the structural features that confer tight AR ligand-binding domain fit — including the flattened A-ring — while the double bond at C1–C2 reduces the compound's androgenic potency relative to DHT itself, yielding a more favourable anabolic-to-androgenic ratio. In practice this means meaningful lean-tissue anabolic signalling with a comparatively lower androgenic side-effect burden.
Why does DHB not convert to estrogen, and how does that affect receptor signalling?: DHB is not an aromatase substrate because the 5-alpha-reduced A-ring lacks the structural prerequisites for aromatase-catalysed aromatization. Every anabolic signal generated by DHB therefore flows exclusively through androgen receptor activation — no estrogen receptor pathway is engaged — producing a uniquely clean androgenic stimulus. Compared to boldenone, which aromatizes at roughly 50 % the rate of testosterone, DHB generates zero estrogenic receptor activity.
What syringe gauge is recommended for drawing and injecting Dragon-Pharma 1-Test Cyp 100 from the 10 ml vial?: A 21-gauge needle is generally used to draw the oil-based solution from the multi-dose vial; a finer 23–25 gauge needle is then swapped for the actual intramuscular injection to minimise tissue trauma. Because DHB in oil can be viscous, warming the vial briefly in warm water (not boiling) facilitates smooth aspiration without degrading the active compound.
How should the 10 ml vial of 1-Test Cyp 100 be stored after first use?: After the rubber septum has been punctured for the first time, store the vial upright at room temperature (15–25 °C), away from direct light and heat. Refrigeration is not required and may increase solution viscosity; however, if ambient temperatures exceed 30 °C consistently, brief refrigeration is acceptable. The multi-dose vial should be used within 28 days of first puncture, and the stopper should be swabbed with an alcohol wipe before each draw. (2) angle_used

Manufacturer

Dragon-Pharma's injectable product portfolio is built around a deliberate range architecture: concentration tiers, ester variants, and carrier-oil specifications are selected to match the pharmacokinetic demands of specific active compounds rather than to standardise across a universal format. Within the injectable androgenic line, 1-Test Cyp 100 represents the company's dihydroboldenone entry point — a High-Concentration, single-compound, cypionate-esterified formulation positioned as the foundational DHB option in a catalogue that extends across esters, stacks, and concentration levels. Dragon-Pharma's quality infrastructure for its injectable vials requires that each finished lot clear a defined analytical sequence before release: HPLC quantification of the active DHB cypionate content against a certified reference standard, sterility confirmation via LAL endotoxin assay, and fill-volume verification across the production run — batch-level records for all three are maintained internally and, for third-party-verified lots, corroborated by accredited external laboratory data.

Product details

Brand	Dragon-Pharma
Active ingredient	dihydroboldenone
Also known as	1-Testosteronee, DHB, Dihydroboldenon, 1-Test Cyp 100, Dragon-Pharma 1-Testosteronee
Strength	100 mg
Form	Vial
Pack size	1 piece
Item number	INJ-DHB-DRA-100-001

Reviews

4.5/5

2 reviews

Rating: 5 out of 5 starsnitroVerified purchaseJul 23, 2026
solid lean gains
Running 400mg/wk for 10 weeks alongside a low carb cut. Dropped from 96kg to 91kg but strength actually went up, bench went from 120 to 130kg. No water retention like test e gives me, which is the whole point. Bloods at week 8 showed test at 3800 ng/dl, hematocrit was 48 which is fine. Libido was through the roof weeks 3-8 then levelled off. PIP was basically nothing after the first two jabs. Would run again no question
Rating: 4 out of 5 starsDario E.Verified purchaseJun 12, 2026
good compound, slow start
decnet product but took almost 3 weeks to really feel it kicking in. 300mg/wk first cycle with this compound, by week 4 the pumps and fullness were proper good. Oil is on the thicker side so had a couple sore spots early on. Gained about 4kg lean over 12 weeks. Price is a bit steep compared to regular test e but the lack of bloat makes it worth it for a cut

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

DHB 100mg/ml 10x1ml Ampoules by Imperia Laboratories

Long-Acting Formula

DHB 100mg/ml 10x1ml Ampullen by Imperia Laboratories

Dihydroboldenone (DHB) at 100 mg/ml in single-dose ampoule format is characterised principally by its pharmacokinetic profile: an esterless parent compound paired with a short-chain ester that determines how rapidly the active steroid enters systemic circulation and how long meaningful plasma concentrations persist. The acetate or base form of DHB exhibits a markedly shorter plasma half-life than longer-ester analogues, which translates directly into injection frequency decisions and peak-to-trough ratio management during a cycle. Quality assurance at Imperia Laboratories is enforced through reversed-phase HPLC quantification of active-ingredient concentration and LAL endotoxin testing on every production batch — each ampoule sealed and released only after both gates are passed.

€48.00

Pharma Grade

DHB 150mg/ml 10ml Vial by Master Pharma

Master Pharma DHB delivers dihydroboldenone at a concentrated 150mg/ml in a sterile 10ml vial — a form engineered to bypass the hepatic first-pass metabolism that severely limits the practical bioavailability of oral dihydroboldenone preparations. Because the compound is administered intramuscularly, virtually the entire injected dose enters systemic circulation intact, a pharmacokinetic advantage no oral DHB formulation can replicate. Batch-released under GMP protocols; each vial carries independent HPLC concentration verification and LAL endotoxin certification before distribution.

€48.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00